Posted by Michael Wonder on 08 Sep 2022
MHRA approves olaparib for high-risk, early stage breast cancer
7 September 2022 - The Institute of Cancer Research, London, celebrates the news that the precision medicine olaparib has been approved by the UK regulator, the Medicines and Healthcare products Regulatory Agency, for patients with high risk, early stage breast cancer and inherited faults in their BRCA1 or BRCA2 genes.
The drug offers women diagnosed with early stage, inherited breast cancer an additional treatment that can help prevent their cancer recurring and improve their survival.
